

AD_____

Award Number: DAMD17-00-1-0057

TITLE: Conditional Estrogen Receptor Knockout Mouse Model for
Studying Mammary Tumorigenesis

PRINCIPAL INVESTIGATOR: Sohaib A. Khan, Ph.D.

CONTRACTING ORGANIZATION: University of Cincinnati
Cincinnati, Ohio 45267-0553

REPORT DATE: January 2004

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those
of the author(s) and should not be construed as an official Department
of the Army position, policy or decision unless so designated by other
documentation.

20040503 046

REPORT DOCUMENTATION PAGE

*Form Approved
OMB No. 074-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)	2. REPORT DATE January 2004	3. REPORT TYPE AND DATES COVERED Final (1 Jan 2000 - 31 Dec 2003)
4. TITLE AND SUBTITLE Conditional Estrogen Receptor Knockout Mouse Model for Studying Mammary Tumorigenesis		5. FUNDING NUMBERS DAMD17-00-1-0057
6. AUTHOR(S) Sohaib A. Khan, Ph.D.		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Cincinnati Cincinnati, Ohio 45267-0553		8. PERFORMING ORGANIZATION REPORT NUMBER
<i>E-Mail:</i> sohaib.khan@uc.edu		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER
11. SUPPLEMENTARY NOTES		
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited		12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) In addition to accomplish the main goal of this grant proposal, i.e. to generating mice with estrogen receptor (ER) alpha gene ablation in the mammary gland of mcie, we have also carried out other tasks. A summary of our findings follows: (1) In order to identify targets of ER-alpha, ER-beta genes, we used microarray and profiled the targets for estrogen and bis phenol-A. This will be of help in understanding the mechanism by which different ligands function in the breast cancer cells. (2) We identified the F-domain of ER-alpha as playing an important role in the regulation of ER activity. (3) We constructed ER-alpha targeting vectors and generated ER-alpha embryonic cell lines. (4) We generated floxed ER-alpha mice, which will be used to generate tissue specific mice (e.g. mammary). Thus these tools and results will be of great use in understanding breast cancer disease process with reference to the role of estrogen receptor.		
14. SUBJECT TERMS Breast cancer		15. NUMBER OF PAGES 13
		16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified
		20. LIMITATION OF ABSTRACT Unlimited

Table of Contents

	<u>Page Numbers</u>
1. Front Cover	1
2. Standard Form 298, Report Documentation Page	2
3. Table of Contents	3
5. Introduction	4
6. Body	4 - 12
7. Key research Accomplishments	12
8. Reportable Outcomes	12
9. Conclusions	13
10. References	14

INTRODUCTION

Breast cancer is among the most devastating diseases affecting women. The risk for a North American women getting breast cancer has doubled since 1940, and at present one woman in eight is at risk of developing the disease. It is generally believed that estrogens play a significant role in the development of breast cancer. The mitogenic action of estrogen is amplified by the hormone-dependent transcription factors, estrogen receptor α (ER α) and estrogen receptor β (ER β). Because of its pivotal role in the normal physiology of breast, ER α has become a target for pharmacological intervention in breast cancer. This contention is strengthened by observations that the estrogen receptors are hormone dependent transcription factors that regulate the expression of growth factors and protooncogenes in breast tumor cell lines. Moreover, the growth and progression of many breast cancers are dependent upon estrogen, making measurement of ER α standard in the treatment decisions for patients with breast cancer. The ER α negative breast tumors are generally associated with faster growing and more aggressive tumors than the ER α positive tumors, which can be controlled with antiestrogen therapy. Towards understanding the role of ER α in breast tumorigenesis, we have initiated a program, using gene-targeting technology to ablate ER α gene in the mammary gland. This mouse model is expected to be of great use in addressing the role of estrogen receptor in mammary tumorigenesis.

In the final Progress Report we will describe our work with ER α mutant (K303R); yeast two-hybrid studies with ER α /ER β heterodimerization; non-genomic action of estradiol and our accomplishments related to the main focus of the DOD-funded project, i.e. generation of conditional ER α knock out (KO) mice.

BODY

1. Study on human ER-K303R mutant:

We have used the cDNA encoding ER (K303R) to stably transfect an ER null cell line called C4-12, using the G418 selection system. The stable cell line was tested for expression of the transgene by Western blot analysis.

2. Protein-protein interactions between ER α and ER β .

We have expanded the yeast two-hybrid experiments to study the interaction between ERs and the receptor coactivators and concluded that the F-domain of the receptor affects the estrogen-dependent interactions between p160 coactivators and the estrogen – bound ERs.

3. Studies with C4-12 breast cancer cells.

In this study, our most exciting achievement has been the establishment of breast cancer cell lines expressing ER α , ER β , K303R or ER α/β . We have now systematically begun to analyze these cell lines to determine the target genes for ERs. In the first set of such an experiments, we challenged the ER α expressing cell line with vehicle, estradiol or an environmental estrogen bis phenol-A (BPA) and analyzed the gene expression pattern with microarray technology. The

intriguing observation is that some genes that are induced by estradiol are actually inhibited by BPA and the two ligands showed a different expression patterns. We have further confirmed the expression of some of these genes by real time PCR and focused on one of the protooncogenes, c-myb whose expression has been previously seen in breast cancer patients. We have cloned and sequenced its promoter, which revealed no consensus estrogen response element (ERE). Our current hypothesis is that C-myb is induced by estradiol and BPA through AP-1 elements on c-myb promoter.

4. Estrogen receptor- α gene-targeting vector and ES cell lines:

We have finished the construction of the ER α targeting vector and produced ES cell lines. The details are provided below:

Construction & characterization of the ER α gene-targeting vector.





Figure 1 Wild-type ER- α exon3 locus and the targeting construct

In order to make the targeting vector, we originally focused to delete exon 2 and obtained a mouse genomic DNA clone harboring a 10kb BamHI fragment of mouse ER α gene. We however revisited the issue and decided to focus on deleting exon 3. This was prompted by the fact that knockout mice carrying exon 2 deletion in the genomic KO (reported by Ken Korach) some low levels of truncated ER α expression persisted.



We obtained the exon 3 DNA fragment (pBC-ER α -BamHI) from Jan Ake Gustafsson (Karolinska Institute). The pBC-ER α -BamHI construct was amplified and analyzed by restriction enzyme digestion and sequencing (fig. 1). We have confirmed that the 9.2 kb insert is the ER α genomic fragment and harbors exon3 (fig. 2).



Utilizing a series of cloning steps, we designed the ER α conditional Knockout-targeting construct according to a scheme presented in Figure 1. In order to screen the targeted ES cell clones more efficiently, we introduced a negative selection gene, HSV TK, into the Clal site of pBCSK vector (Stratagene). The "Floxed PGK-Neo cassette" was inserted into the Eco47III site on the 3' side of exon3. The 46bp LoxP-BamHI fragment was inserted into the Nhel site on the 5' side of exon3. The targeting construct was confirmed by BamHI Digestion (fig 3) and DNA sequencing. The complete sequence of the 12.6 kb targeting construct was fully sequenced. We then blasted our DNA sequence in the Celera gene and found 97% homology with the Celera mouse genome. At this stage we decided to electroporate the targeting construct into the ES cells.

Electroporation of the targeting construct into ES cells.

The KO construct was linearized with PmlI and electroporated into embryonic stem (ES) cells. Most ES cells were killed by G418 treatment, but 30 single clones were obtained after the selection with G418 at a concentration of 240 μ g/ml. The ES clones were cultured in 24-well plates to full confluence and lysed overnight for the isolation of their genomic DNA. 5' and 3' PCR primers were designed to detect the targeted allele (fig. 4). The ES clones have been screened with ERKO 3' and 5' primers to detect the 5.2kb and 4.7 kb targeted alleles, but our PCR screening did not find targeted clones. The reason that most ES cells were killed was because of the reduced G418 resistance, resulting from a natural mutation in the Neo gene on our construct.




Repairing the Neo gene on the targeting construct


We decided to fix the mutation in our knockout construct with site-directed mutagenesis. The mutation was repaired on the pFloxNeo plasmid. The mutant Neo on the KO construct was then replaced with the fixed Neo gene. The KO construct was then linearized with PmlI and electroporated into ES cells again.

Screening of targeted ES clones

After electroporation, about 290 ES clones were amplified after the G418 selection. Genomic DNA was extracted from the lysate of the ES cells. Two sets of PCR primers, ERKO 5'-Neo and ERKO 3'-Neo, were used to screen the targeted ES clones. Both 5' and 3' primers are from flanking region of the targeting locus (fig. 4). 3 positive clones were identified by PCR (figure 5).



For confirmation, the 5' and 3' PCR products of the positive clones were subjected to Southern Blot with 3' and 5' outside probes. The PCR Southern experiment confirmed that the PCR products are from the targeted alleles (figure 6).



Genomic DNA from the positive clones was digested with BamHI and probed with 5' outside probe, a 1.1 kb DNA fragment generated with NotI and PmlI

double digestion on the ERKO construct. Two positive clones, D34 and D93, were re-confirmed by the Southern Blot (figure 7).






Figure 7 Confirmation of the targeted ES clones with Southern Blot. Genomic DNA of the targeted clones identified by the PCR screening was digested with BamHI and probed with the 1.1 kb 5' outside probe. The wild type ES cells (WT) showed 9.2kb bands. The target ES clones, 34 and 93, showed 4.6kb targeted allele bands in addition to the 9.2 kb wild type bands.

Identification of the Floxed ER α ES clones


It has been reported that insertion of a Neo gene will affect the phenotype of knockout mice. We decide to delete the Neo gene in our Targeted ES clones. The Cre recombinase plasmid was electroporated into the mixed targeted clones (D34 and D93) to delete the Floxed Neo gene. We got 30 G418 sensitive clones from the selection. The clones were screened with ERKO 5'-Neo and ERKO 3'-Neo primers. No PCR product can be amplified from the 30 clones. This result confirmed that the Neo gene has been deleted from our ES clones. Since there are three possible recombinations by the Cre treatment, these negative clones were further screened with primers that amplify the region between LoxP1 and LoxP3. 1050bp fragment will be amplified if only the Floxed Neo gene is deleted. A 500bp DNA fragment will be amplified if both exon 3 and the Floxed Neo are deleted by Cre recombinase. Since only one allele of a ES clone was expected to be targeted, we will see the 970bp wild type allele band in all the ES clones. As the Floxed Neo gene was deleted in all the clones we did not see the 1.7 kb band resulting from the recombination of LoxP1 and LoxP2. We found 3 Floxed ER α ES clones in our screen (Figure 8). One of the 3 identified clones, E84, was confirmed with Southern blot using 3' probe (Figure 9).



Generation of the Floxed ER α mice

The ES cells from clone E84 were introduced into pseudo-pregnant mice. Four agouti males were born. Breeding with black 6 females, a 95% agouti chimera generated 4 agouti pups in the second litter. Genotyping the mouse-tails showed that 3 of the 4 agoutis are Floxed ER α mice (Figure 10). We are breeding the

Floxed ER α mice to generate the homozygote. Crossing the Floxed ER α mice with WAP-Cre mice will generate the MERKO mice.



Key Research Accomplishments:

- Identification of the target genes of estrogen and BPA in breast cancer cell line expressing only ER α .
- Contribution to the F-domain of ER α in the estrogen-dependent recruitment of coactivators.
- Construction of the ER α targeting vector and generation of Floxed ER α ES cell lines.
- Generation of Floxed ER α mice for generating mammary epithelial specific ER α KO mice.

REPORTABLE OUTCOMES

Singleton, D., and Khan, S. "Estrogen receptor dependence of MAP-kinase activation in breast and uterine tumor cells Annual Meeting of the "ENDOCRINE SOCIETY", Denver, Co (2001)

Singleton DW, Feng Y, Burd C, Khan SA. Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells. *Endocrinology*. 2003 Jan;144(1):121-8.

Singleton DW and Khan SA. Xenoestrogen exposure and mechanisms of endocrine disruption. *Front Biosci*. 2003 Jan 1;8:s110-8. Review.

Singleton DW, Feng Y, Burd C, Khan SA. Nongenomic Action of Estrogen Receptor Ligands Is not Sufficient to Induce Proliferation of Human Endometrial Adenocarcinoma Cells. (abstract submitted for presentation at The Endocrine Society Meeting, June 2002)

Feng Y, Singleton D and Khan S. Conditional Estrogen Receptor Knockout Mouse Model For Studying Mammary Tumorigenesis. (abstract submitted for presentation at The Era of Hope Meeting, September 2002)

David W. Singleton, Yuxin Feng, Yangde Chen, Steve J. Busch, Adrian V. Lee, Alvaro Puga and Sohaib A. Khan. Bisphenol-A and Estradiol Exert Novel Gene Regulation in a Human Breast Cancer Cell Line (In revision for Molecular and Cellular Endocrinology)

Jun Yang, David W. Singleton, Elwood V. Jensen and Sohaib A. Khan. The F-domain of Estrogen Receptor-Alpha Inhibits Ligand Induced Receptor Dimerization. (preparing for submission to the Proc. Natl. Acad. Sci.)

Cell Lines:

We have generated yeast cell lines transformed with different pairs of the estrogen receptor.

CONCLUSIONS

Estrogen receptor α plays a key role in breast cancer. However, little is known about the involvement of the receptor in the progression of breast tumorigenesis. Towards achieving our overall goal of generating ER knockout mice for studying mammary tumorigenesis, we had proposed to generate ER α conditional knockout mice. We have successfully generated ER α targeting construct, Floxed ER α ES cell line and the Floxed ER α mice for use in generating ER α knockout mice. We are breeding the Floxed ER α mice with WAP-Cre mice. MERKO mice will be generated in several months. In addition, we established breast cancer cell lines expressing different ERs; identified novel ER α target genes regulated by E2 and BPA and defined the function of F domain of ER α in coactivator recruitment.

Our mammary gland specific ER α knockout project is highly innovative in that no mouse model is available where the ER gene is only inactivated in the mammary epithelial cells. The conditional gene knockout is a useful advancement in the field and its use in understanding issues related to breast cancer will have tremendous advantages. We will use the mouse model to determine if the mammary gland functions in the absence of estrogen receptor and whether mammary tumors can be induced by DMBA in ER α negative mice. In the future, using a transgenic approach, we will reintroduce variant ERs into the MERKO mice. These mice will then express defective ER only in the mammary cells and

can be useful to determine the consequence of aberrant ER expression on tumor development.

The generation of Floxed ER α mice provides a pivotal animal model, not only important to study the role of ER α in breast tumorigenesis, but also useful to study the biological functions of ER α in other organs, such as brain and heart. Crossing the Floxed ER α mice with tissue specific expressing Cre mice, tissue specific ER α knockout mice in ER α effective organs, brain, heart, bone and prostate, can be generated.

REFERENCES

- Fuqua SA, Wiltschke C, Zhang QX, Borg A, Castles CG, Friedrichs WE, Hopp T, Hilsenbeck S, Mohsin S, O'Connell P, Allred DC. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. *Cancer Res* 2000; 60:4026-9.